Streamlining Skyrizi Prior Authorization for OB/GYN Practices

Managing Skyrizi prior authorization for OB/GYN patients with complex co-morbidities requires robust automation. Klivira's platform simplifies the process, ensuring timely access to critical biologic therapies.

OB/GYN practices increasingly encounter patients on specialized biologic therapies like Skyrizi (risankizumab) for co-existing conditions such as psoriatic arthritis or Crohn's disease. Navigating prior authorization (PA) for these medications, which are outside the typical OB/GYN formulary, adds significant administrative burden. Klivira provides the operational intelligence to manage these complex PA workflows efficiently.

Skyrizi (Risankizumab) in the OB/GYN Clinical Context

Skyrizi, an IL-23 inhibitor, is indicated for plaque psoriasis, psoriatic arthritis, and Crohn's disease. While not a primary OB/GYN medication, women's health specialists frequently co-manage patients with these chronic conditions, particularly during pregnancy, lactation, or pre-conception counseling. Understanding the specific PA requirements for Skyrizi is crucial for ensuring continuity of care for these complex patients within an OB/GYN practice.

Prior Authorization Triggers for Skyrizi (Risankizumab)

Prior authorization for Skyrizi is driven by its approved indications, not OB/GYN-specific conditions. For an OB/GYN practice managing a patient on or initiating Skyrizi, the PA criteria will focus on the underlying dermatologic or gastroenterologic diagnosis. This necessitates close coordination with other specialists and a comprehensive understanding of payer policies for biologic agents used in chronic autoimmune conditions.

Key Documentation for Skyrizi PA in Co-Managed OB/GYN Cases

Diagnosis of an approved indication (plaque psoriasis, psoriatic arthritis, or Crohn's disease).
Documentation of disease severity and activity, often using validated clinical scores.
History of prior systemic therapies, including biologics, and documented lack of efficacy or intolerance.
Absence of contraindications, such as active infections, as per prescribing information.
Considerations for pregnancy and lactation status, including shared decision-making discussions with the patient.

Navigating Biologic Therapy Management in Women's Health

The management of biologic therapies like Skyrizi during pregnancy or for women of childbearing age presents unique challenges. OB/GYN practices must consider fetal exposure, potential maternal complications, and the impact of discontinuing therapy. While specific guidelines for Skyrizi in pregnancy are managed by the primary prescribing specialist, the OB/GYN team plays a vital role in monitoring, counseling, and coordinating care, requiring an integrated PA approach.

Common PA Denial Reasons for Biologics in Co-managed OB/GYN Cases

Denials for Skyrizi PA often stem from insufficient documentation of medical necessity related to its primary indications. This can include a lack of documented trial and failure of conventional therapies, inadequate disease activity scores, or missing information regarding contraindications. For OB/GYN practices co-managing these patients, ensuring complete and accurate documentation from the referring specialist is paramount to avoid delays or denials.

Klivira's Role in Streamlining Complex Biologic PAs for OB/GYN

Klivira's platform is engineered to manage the complexities of prior authorization for specialized medications, even when they fall outside a practice's core specialty. By integrating with EMRs and applying payer-specific logic, Klivira automates the aggregation of necessary clinical data, identifies specific documentation requirements for drugs like Skyrizi, and facilitates efficient submission. This reduces the administrative burden on OB/GYN staff, allowing them to focus on patient care.

Frequently asked questions

Why would an OB/GYN practice need to manage Skyrizi PA?

An OB/GYN practice would manage Skyrizi PA for patients with co-morbid conditions such as plaque psoriasis, psoriatic arthritis, or Crohn's disease, especially when these patients are pregnant, lactating, or planning pregnancy. The OB/GYN team supports the overall health management of these individuals.

What are Skyrizi's approved indications?

Skyrizi (risankizumab) is an IL-23 inhibitor approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe Crohn's disease in adults. These are the conditions for which prior authorization criteria are established by payers.

Are there specific OB/GYN guidelines for Skyrizi use during pregnancy?

While Skyrizi is not an OB/GYN-specific medication, clinical decisions for patients on biologics during pregnancy typically involve multidisciplinary care. This often means referencing guidelines from rheumatology or gastroenterology societies for disease management, alongside ACOG Practice Bulletins and SMFM Consult Series for obstetric care.

How does Klivira support PAs for biologics in complex OB/GYN cases?

Klivira integrates with EMRs to aggregate patient data, applies payer-specific rules for complex drug PAs, and streamlines the submission process. This minimizes manual effort for conditions managed in co-consultation, ensuring that documentation for Skyrizi's primary indications is accurately compiled and submitted.

What documentation is crucial for Skyrizi PA approval?

Crucial documentation for Skyrizi PA approval must support the diagnosis of an approved indication (e.g., plaque psoriasis, psoriatic arthritis, Crohn's disease), evidence of disease severity, and a history of failed prior systemic therapies as per payer medical policy and clinical guidelines.